TG Therapeutics

Intravenous therapy

FDA Extends PDUFA Goal Date of Ublituximab for MS

The US Food and Drug Administration (FDA) extended the Prescription Drug User Fee Act (PDUFA) goal date for ublituximab to December 28, 2022, as announced in a press release by TG Therapeutics. Formerly known as TG-1101, ublituximab is an investigational monoclonal antibody to treat multiple sclerosis (MS). It targets CD20-expressing B-cells that are designed to…

Next post in MS News Briefs